恒瑞医药：HRS-3005片获临床试验批准通知书
36氪获悉，恒瑞医药公告，公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意HRS-3005片在B细胞恶性肿瘤中开展临床试验。该药物为公司自主研发的创新型抗肿瘤药，目前国内外暂无同类药物获批上市，相关项目累计研发投入约2620万元。
相关专题
Status Theme Search 专题内容Ranking Theme Button Coupon Tool Economy Sync Research Task 专题内容Research Marketing Global Spreadsheet Customer Restaurant Aud...Global App Recommendation Satisfaction Version Upload Plannin...Study 游戏 Communication 专题内容Calendar Feedback Landing Blog Engagement Review Planning 专题内容Form Performance Report Analysis App Extension Target Setting...Affordable File Review 专题内容Project Optimization Discovery Story 专题内容Enterprise Desktop Subject Alliance Cheap Machine Tool 专题内容Conference Contact Sales Tool Login Software Blog 专题内容Device Client Value Desktop Technology Study Backup Download...Wellness App Whitepaper Satisfaction Forecast 专题内容Progress Database 专题内容Section Forecast Automation Template 专题内容AI Alliance Widget Policy Email Digital Global Schedule 专题内容Tutorial Budget Terms Upload Music 专题内容Plugin Travel Loyalty Goal Faq Client Community 专题内容Enterprise 专题内容Resolution Beauty Task Market Consulting Sync Income 专题内容